• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 7
  3. Author

Online ISSN: 2515-8260

Volume9, Issue7

Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

    Dr. Yogesh Ramakant Jadhav, Dr Abhijit R. Katkar, Dr. Asit Choudhary, Dr Prasad Hake

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 7, Pages 5745-5748

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Benign prostatic hyperplasia (BPH) is highly prevalent in elderly men and often results in lower urinary tract symptoms (LUTS). The present study was conducted to compare the efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Materials & Methods: 78 patients of diagnosed with LUTS secondary toBPHwere divided into 2 groups. Group I were given tadalafil 5 mg and group II tamsulosin 0.4 mg. Maximum flow rate (Qmax), Postvoid residual urine (PVR), International Prostate Symptom Score (IPSS), International Prostate Symptom Score Quality of life (IPSS QoL) and Sexual Health Inventory for Men (SHIM) scoring were compared.
Results: mean prostate size in group I was 32.5 gram and in group II was 30.1 gram. Qmax was 13.6 ml/sec in group I and 12.8 ml/sec in group II. PVR was 51.4 ml in group I and 83.2 ml in group II. IPSS was 12.7 in group I and 14.9 in group II, IPSS QoL was 2.3 in group I and 3.0 in group II. The difference was significant (P< 0.05).
Conclusion: Once daily tadalafil 5 mg is well tolerated and can be considered for the treatment of LUTS secondary to BPH when associated with ED
Keywords:
    Benign prostatic hyperplasia Lower urinary tract symptoms Men
  • PDF (195 K)
  • XML
(2022). Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Journal of Molecular & Clinical Medicine, 9(7), 5745-5748.
Dr. Yogesh Ramakant Jadhav, Dr Abhijit R. Katkar, Dr. Asit Choudhary, Dr Prasad Hake. "Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia". European Journal of Molecular & Clinical Medicine, 9, 7, 2022, 5745-5748.
(2022). 'Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia', European Journal of Molecular & Clinical Medicine, 9(7), pp. 5745-5748.
Assessment of efficacy of tadalafil with tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Journal of Molecular & Clinical Medicine, 2022; 9(7): 5745-5748.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 4
  • PDF Download: 37
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus